<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    9428952
   </pmid>
   <datecreated>
    <year>
     1998
    </year>
    <month>
     02
    </month>
    <day>
     13
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1998
    </year>
    <month>
     02
    </month>
    <day>
     13
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     11
    </month>
    <day>
     19
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      1079-2082
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       54
      </volume>
      <issue>
       24
      </issue>
      <pubdate>
       <year>
        1997
       </year>
       <month>
        Dec
       </month>
       <day>
        15
       </day>
      </pubdate>
     </journalissue>
     <title>
      American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
     </title>
     <isoabbreviation>
      Am J Health Syst Pharm
     </isoabbreviation>
    </journal>
    <articletitle>
     ASHP Therapeutic Position Statement on the safe use of niacin in the management of dyslipidemias. American Society of Health-System Pharmacists.
    </articletitle>
    <pagination>
     <medlinepgn>
      2815-9
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext>
      ASHP supports the use of niacin as an effective therapy for the management of dyslipidemias in adults. Successful and safe therapy requires ongoing supervision and instruction by qualified health care providers to monitor the efficacy of therapy and minimize niacin's potential for adverse effects. Because many niacin products are available without a prescription, pharmacists are in a unique position to help ensure that patients make the best use of this medication.
     </abstracttext>
    </abstract>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Guideline
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Practice Guideline
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     Am J Health Syst Pharm
    </medlineta>
    <nlmuniqueid>
     9503023
    </nlmuniqueid>
    <issnlinking>
     1079-2082
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      59-67-6
     </registrynumber>
     <nameofsubstance>
      Niacin
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Am J Health Syst Pharm. 1997 Dec 15;54(24):2803
     </refsource>
     <pmid version="1">
      9428949
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Monitoring
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug-Induced Liver Injury
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Gastrointestinal Diseases
     </descriptorname>
     <qualifiername majortopicyn="N">
      chemically induced
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hyperlipidemias
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Niacin
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pharmaceutical Services
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Skin Diseases
     </descriptorname>
     <qualifiername majortopicyn="N">
      chemically induced
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1998
     </year>
     <month>
      1
     </month>
     <day>
      16
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1998
     </year>
     <month>
      1
     </month>
     <day>
      16
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1998
     </year>
     <month>
      1
     </month>
     <day>
      16
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     9428952
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

